Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Journal of Medicinal Chemistry|December 1, 1987
Potent vasopressin antagonists modified at the carboxy-terminal tripeptide tailF E Ali, H L Chang, W F Huffman, et al.Journal of Medicinal Chemistry|April 1, 1989
A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activityW F Huffman, C Albrightson-Winslow, B Brickson, et al.Journal of Medicinal Chemistry|April 1, 1988
Design, synthesis, and biological activity of a peptide mimic of vasopressinW M Bryan, J C Hempel, W F Huffman, et al.The Journal of Pharmacology and Experimental Therapeutics|January 1, 1991
Vasopressin antidiuretic agonist and antagonist activity in dogs: structural and stereochemical relationship between bridge and carboxyl terminusC R Albrightson-Winslow, B Brickson, D P Brooks, et al.Biochemical and Biophysical Research Communications|March 15, 1989
Peptide substrates and inhibitors of the HIV-1 proteaseM L Moore, W M Bryan, S A Fakhoury, et al.Bioorganic & Medicinal Chemistry Letters|March 31, 2000
Novel peptidomimetic hematoregulatory compoundsD A Heerding, M Abruzzese, D Alberts, et al.Bioorganic & Medicinal Chemistry|September 1, 1994
Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonistW E Bondinell, R M Keenan, W H Miller, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2001
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized ratM W Lark, G B Stroup, R A Dodds, et al.The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.Bioorganic & Medicinal Chemistry Letters|August 31, 2001
Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agentsM A Seefeld, W H Miller, K A Newlander, et al.Pageof 4